Juan Carlos Montero

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 16

Top Topics

Endoplasmic Reticulum

Signaling Pathway

Top Venues

International journal of molecular sciences

Clinical science (London, England : 1979)

Journal of experimental & clinical cancer research : CR

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Eduardo Terán, Rebeca Lozano, Cesar A Rodriguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M Asunción Gómez, Daniel Morchón, Juan Carlos Montero, Jose Maria Sayagues Manzano, M Dolores Ludeña, Emilio Fonseca
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer. Cancer medicine 13 (17) (2024)
Luis Miguel Chinchilla-Tábora, Juan Carlos Montero, Luis-Antonio Corchete, Idalia González-Morais, Edel Del Barco Morillo, Alejandro Olivares-Hernández, Marta Rodríguez, Jose Maria Sayagues Manzano, María Dolores Ludeña de la Cruz
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. International journal of molecular sciences 25 (4) (2024)
Luis Miguel Chinchilla-Tábora, Juan Carlos Montero, Luis-Antonio Corchete, Idalia González-Morais, Edel Del Barco Morillo, Alejandro Olivares-Hernández, Marta Rodríguez, Jose Maria Sayagues Manzano, María Dolores Ludeña de la Cruz
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. International journal of molecular sciences 25 (4) (2024)
Luis Miguel Chinchilla-Tábora, Juan Carlos Montero, Luis-Antonio Corchete, Idalia González-Morais, Edel Del Barco Morillo, Alejandro Olivares-Hernández, Marta Rodríguez, Jose Maria Sayagues Manzano, María Dolores Ludeña de la Cruz
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. International journal of molecular sciences 25 (4) (2024)
Juan Carlos Montero, Sofía Del Carmen, Mar Abad, José M Sayagués, Antonio Barbáchano, Asunción Fernández-Barral, Alberto Muñoz, Atanasio Pandiella
An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Jose Maria Sayagues Manzano, Juan Carlos Montero, Andrea Jiménez-Pérez, Sofía Del Carmen, Marta Rodríguez, María Del Rosario Vidal Tocino, Enrique Montero, Julia Sanz, Mar Abad
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival. International journal of molecular sciences 24 (9) (2023)
Jose Maria Sayagues Manzano, Juan Carlos Montero, Andrea Jiménez-Pérez, Sofía Del Carmen, Marta Rodríguez, María Del Rosario Vidal Tocino, Enrique Montero, Julia Sanz, Mar Abad
Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival. International journal of molecular sciences 24 (9) (2023)
Sheila Almaraz Postigo, Juan Carlos Montero
Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical science (London, England : 1979) 137 (1) (2022)
Sheila Almaraz Postigo, Juan Carlos Montero
Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical science (London, England : 1979) 137 (1) (2022)
Alba Rodriguez, Luis-Antonio Corchete, José Antonio Alcazar, Juan Carlos Montero, Marta Rodríguez, Luis Miguel Chinchilla-Tábora, María Del Rosario Vidal Tocino, Carlos Moyano, Saray Muñoz-Bravo, Jose Maria Sayagues Manzano, Mar Abad
Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups. Cancers 14 (17) (2022)
Juan Carlos Montero, Elisa Calvo-Jiménez, Sofía Del Carmen, Mar Abad, Alberto Ocaña, Atanasio Pandiella
Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Sheila Almaraz Postigo, Juan Carlos Montero
Neuregulin modulates hormone receptor levels in breast cancer through concerted action on multiple signaling pathways. Clinical science (London, England : 1979) 137 (1) (2022)
Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (18) (2021)
Juan Carlos Montero, Atanasio Pandiella
PDCD4 limits prooncogenic neuregulin-ErbB signaling. Cellular and molecular life sciences : CMLS 78 (4) (2020)
Ariana Centa, Ruth Rodríguez-Barrueco, Juan Carlos Montero, Atanasio Pandiella
The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. Molecular oncology 12 (7) (2018)
Ana Orive-Ramos, Samuel Seoane, Alberto Ocaña, Atanasio Pandiella, Juan Carlos Montero
Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications. Molecular oncology 11 (12) (2017)